EA202092032A1 - Т-клеточный рецептор, специфичный в отношении ny-eso-1/lage-1, и его применения - Google Patents

Т-клеточный рецептор, специфичный в отношении ny-eso-1/lage-1, и его применения

Info

Publication number
EA202092032A1
EA202092032A1 EA202092032A EA202092032A EA202092032A1 EA 202092032 A1 EA202092032 A1 EA 202092032A1 EA 202092032 A EA202092032 A EA 202092032A EA 202092032 A EA202092032 A EA 202092032A EA 202092032 A1 EA202092032 A1 EA 202092032A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tcr
lage
eso
cell receptor
applications
Prior art date
Application number
EA202092032A
Other languages
English (en)
Inventor
Карина Венер
Манон Вайс
Original Assignee
Медиджин Иммьюнотерапиз Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медиджин Иммьюнотерапиз Гмбх filed Critical Медиджин Иммьюнотерапиз Гмбх
Publication of EA202092032A1 publication Critical patent/EA202092032A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Epoxy Resins (AREA)

Abstract

Настоящее изобретение относится к выделенному Т-клеточному рецептору (TCR), специфическому в отношении NY-ESO-1/LAGE-1, и полипептиду, содержащему функциональную часть TCR. Настоящее изобретение также относится к мультивалентному комплексу TCR, нуклеиновой кислоте, кодирующей TCR, клетке, экспрессирующей TCR, фармацевтической композиции, содержащей TCR. Настоящее изобретение также относится к TCR для применения в качестве лекарственного средства, в частности к TCR для применения в лечении злокачественного новообразования.
EA202092032A 2018-02-26 2019-01-28 Т-клеточный рецептор, специфичный в отношении ny-eso-1/lage-1, и его применения EA202092032A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LU100715 2018-02-26
PCT/EP2019/051963 WO2019162043A1 (en) 2018-02-26 2019-01-28 Nyeso tcr

Publications (1)

Publication Number Publication Date
EA202092032A1 true EA202092032A1 (ru) 2021-04-06

Family

ID=62067761

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092032A EA202092032A1 (ru) 2018-02-26 2019-01-28 Т-клеточный рецептор, специфичный в отношении ny-eso-1/lage-1, и его применения

Country Status (10)

Country Link
US (2) US11267864B2 (ru)
EP (1) EP3555124B1 (ru)
JP (1) JP7068459B2 (ru)
KR (1) KR102490850B1 (ru)
CN (1) CN111819194B (ru)
AU (1) AU2019225798B2 (ru)
CA (1) CA3090917A1 (ru)
EA (1) EA202092032A1 (ru)
TW (1) TWI822726B (ru)
WO (1) WO2019162043A1 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
WO2021163064A2 (en) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN112375136B (zh) * 2020-11-03 2022-06-07 中国科学院微生物研究所 Ny-eso-1特异性t细胞受体筛选及其抗肿瘤用途
CN117425668A (zh) * 2021-03-16 2024-01-19 国立大学法人大阪大学 SARS-CoV-2病毒特异性滤泡辅助性T细胞Tfh
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
WO2023025779A1 (en) * 2021-08-25 2023-03-02 Medigene Immunotherapies Gmbh Combination of antigen specific t cell receptors and chimeric co-stimulatory receptors
CA3234909A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
US20230373950A1 (en) 2022-03-17 2023-11-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230374036A1 (en) 2022-04-21 2023-11-23 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024041761A1 (en) * 2022-08-23 2024-02-29 Medigene Immunotherapies Gmbh Combination of ny-eso-1 specific t cell receptors and chimeric co-stimulatory receptors
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
ATE290020T1 (de) 2001-08-31 2005-03-15 Avidex Ltd Löslicher t zell rezeptor
CA2566363C (en) * 2004-05-19 2014-12-16 Avidex Ltd High affinity ny-eso t cell receptor
EP1756278B1 (en) * 2004-05-19 2008-09-17 MediGene Ltd. Method of improving t cell receptors
HUE038833T2 (hu) 2005-08-05 2018-11-28 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Antigénspecifikus T-sejtek létrehozása
WO2008037943A1 (en) * 2006-09-29 2008-04-03 Medigene Limited Cells transformed with nucleic acid encoding ny-eso t cell receptors
EP2006376A1 (en) 2007-06-21 2008-12-24 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Fusion protein comprising a caspase domain and a nuclear hormone receptor binding domain and methods and uses thereof
EP3828197A1 (en) * 2012-05-22 2021-06-02 The United States of America, as represented by the Secretary, Department of Health and Human Services Pharmaceutical composition comprising host cells encoding anti-ny-eso-1 t cell receptors
CA2906587C (en) * 2013-03-13 2023-02-14 Health Research, Inc. Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
EP3015477B1 (en) * 2013-06-26 2021-08-18 XLifeSc, Ltd. High-stability t-cell receptor and preparation method and application thereof
EP3067366A1 (en) * 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
KR20180043800A (ko) * 2015-09-09 2018-04-30 이뮨 디자인 코포레이션 Ny-eso-1 특이적 tcrs 및 그의 사용 방법
WO2017076308A1 (zh) * 2015-11-04 2017-05-11 广州市香雪制药股份有限公司 识别ny-eso-1抗原短肽的tcr
GB201522592D0 (en) * 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
RU2752528C2 (ru) * 2016-01-06 2021-07-29 Хэлф Ресерч, Инк. Композиции и библиотеки, содержащие рекомбинантные полинуклеотиды, кодирующие Т-клеточные рецепторы, и способы применения рекомбинантных Т-клеточных рецепторов
KR20180135460A (ko) * 2016-04-15 2018-12-20 자임워크스 인코포레이티드 면역치료제를 표적으로 하는 다중-특이적 항원-결합 작제물

Also Published As

Publication number Publication date
JP7068459B2 (ja) 2022-05-16
TWI822726B (zh) 2023-11-21
TW201940506A (zh) 2019-10-16
US20200148738A1 (en) 2020-05-14
AU2019225798B2 (en) 2023-05-18
EP3555124C0 (en) 2024-05-01
WO2019162043A1 (en) 2019-08-29
EP3555124B1 (en) 2024-05-01
CN111819194B (zh) 2024-06-04
CN111819194A (zh) 2020-10-23
CA3090917A1 (en) 2019-08-29
AU2019225798A1 (en) 2020-09-17
JP2021510063A (ja) 2021-04-15
US20220332784A1 (en) 2022-10-20
EP3555124A1 (en) 2019-10-23
KR20200083986A (ko) 2020-07-09
KR102490850B1 (ko) 2023-01-26
US11267864B2 (en) 2022-03-08

Similar Documents

Publication Publication Date Title
EA202092032A1 (ru) Т-клеточный рецептор, специфичный в отношении ny-eso-1/lage-1, и его применения
MX2021001837A (es) Constructos del receptor de celulas t y usos de los mismos.
EA202192327A1 (ru) T-клеточные рецепторы, специфичные к mage-a4
EA201992063A1 (ru) СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1
CO2019007868A2 (es) Anticuerpos agonistas anti-icos y sus usos
EA201991696A1 (ru) Т-клеточные рецепторы, связывающиеся с ny-eso-1, и способы их применения
EA201992131A1 (ru) Высокоаффинные специфичные к mage-a1 tcr и их применение
AR125268A2 (es) Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CR20190276A (es) Nuevos receptores de células t y terapia inmunológica que los utiliza
PE20200006A1 (es) Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap
EA201792420A1 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
MX2020012240A (es) Agentes de ligacion agonistas del receptor tnf.
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
EA201792084A8 (ru) Способы и композиции, связанные с полипептидами - агонистами gpcr
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
WO2018191502A3 (en) Anti-cd137 antibodies and methods of use thereof
BR112019005685A2 (pt) células t com resistência à imunossupressão aumentada
BR112016027805A2 (pt) receptores de células t do anti-papilomavírus humano 16 e7
MX2019011656A (es) Formatos mejorados de receptor de union a antigeno.
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
EA201492048A1 (ru) Полипептиды, связывающиеся с хемокиновым рецептором
EA202092589A3 (ru) Cxcr2-связывающие полипептиды
EA201892774A1 (ru) Антитела
BR112016027595A8 (pt) produtos de peptídeos, composição farmacêutica compreendendo um produto de peptídeo, uso de um produto de peptídeo e método para produzir um produto de peptídeo
EA201890198A1 (ru) Новые белки, специфичные в отношении lag-3